About Us

The OICR Joint Genomics Program’s is an OICR/UHN collaborative initiative led by Dr. Trevor Pugh, which supports basic, translational, and clinical oncogenomics projects.

What We Do

Our program’s mission is to enable complete genomic knowledge that guides the clinical management of cancer patients.

To this end, we:

  • Evaluate and provide access to emerging genome technologies;
  • Industrialize research-grade protocols for high-throughput use; and
  • Implement clinical-grade assays for use in genome-guided clinical research trials.

Our Technology Platform

As one of Ontario’s most advanced sequencing facilities, we can provide support throughout each stage of your project, from initial project design to data analysis using one of Canada’s largest compute infrastructures.

In compliance with ISO 15189, we are committed to upholding high standards of data security and robust infrastructure that are valued by collaborators around the world. We utilize a comprehensive Quality Management System (QMS), Laboratory Information Management System (LIMS), and highly-trained personnel to provide superior quality next generation sequencing services. We are seeking accreditation from the College of American Pathologists (CAP) and the Institute for Quality Management in Healthcare (IQMH), and should receive this distinction in early 2021.

Our sequencing suite, located in downtown Toronto, Ontario, is equipped with: - Illumina NovaSeq 6000 - Illumina HiSeq 2500 - Illumina MiSeq - Illumina NextSeq 550 - Oxford Nanopore MinION

Learn more about our sequencing services here.

Our Impact on Scientific Research

For over 10 years, our teams have been successful in helping research teams across Canada and around the world by solving genomics and analysis problems for the advancement of cancer treatment and management.

Collaboration

The strength of our platform is made possible by partnerships and collaborations with institutions across Ontario, Canada, and the world.

Partner With Us

Contact us about partnerships to join our platform in advancing basic and clinical cancer genomics research.